Ro vs Ivim Health: Broad Catalog vs Metabolic Focus

This article is part of the PlexusDx Education Hub, a library of evidence-based guidance on GLP-1 therapies, weight-management protocols, and the genetic factors that shape metabolic care. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no commercial relationship with Ro or Ivim Health, and no affiliate links or paid placements appear here.

Ro and Ivim Health both live in the telehealth GLP-1 world, but they are built at different scales. Ro is a broad-catalog telehealth service spanning many conditions; Ivim Health is a narrower, metabolic and compounding-focused program. Choosing between them is less about the medicine and more about whether you want a wide platform or a focused one. This overview compares the two and adds the genetic layer both stop short of.

Ro: the broad-catalog telehealth route

Ro (Roman Health) is a subscription-telehealth service covering a wide range of health categories, with GLP-1 weight management one part of the catalog. Intake, provider review, and a prescription for a branded FDA-approved GLP-1 or compounded semaglutide or tirzepatide follow the standard pattern. See the Ro website for current program details.

Ivim Health: the metabolic-focused route

Ivim Health pairs telehealth with a compounded-pharmacy pathway and concentrates on metabolic and weight-management care, routing prescriptions to a retail pharmacy for branded products or a 503A compounding pharmacy for compounded semaglutide or tirzepatide. Its specifics are on the Ivim Health website.

Side by side: what differs in practice

The real contrast is scope. A broad platform can be convenient if you want several health services under one login, while a focused program may offer deeper attention to the metabolic use case and its compounded options. Beyond that, weigh provider type, titration support, fulfillment timing, and which products each currently stocks.

The compound-level science underneath

Scope does not change substance. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual GIP/GLP-1 agonist tirzepatide provide the mechanism and the trial record, including STEP (NEJM 2021), SURMOUNT (NEJM 2022), and SURMOUNT-OSA (NEJM 2024). Whether a broad or focused program delivers the compound, its pharmacology is identical.

Deciding between scope and focus

Scope and focus are a genuine tradeoff, not a ranking. A broad catalog rewards people who want several health services consolidated and are comfortable with a more general workflow. A focused metabolic program rewards people who want the weight-management use case to be the center of attention, including deeper familiarity with compounded options. Rather than assume one wins, picture your next twelve months of care: if it is mostly metabolic, focus tends to pay off; if it spans many needs, breadth may serve you better.

The genetics both programs stop short of

Broad or focused, both end at the prescription. A variant in GLP1R, the receptor every GLP-1 compound targets, along with FTO and TCF7L2, describes the metabolic baseline a protocol acts on. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights across that baseline, and it does not predict how you will respond to any specific medication.

The PlexusDx approach to the same goal

PlexusDx provides semaglutide and tirzepatide through its Weight Management Protocols, offered as Semaglutide Injection ($189/month), Semaglutide Oral, Tirzepatide Injection ($289/month), and Tirzepatide Oral. Starting with the Precision Peptide Genetic Test gives you the upstream context that both broad and focused programs leave out.

Not affiliated: PlexusDx has no commercial relationship with Ro, Ivim Health, or any brand named in this article.

Keep reading on PlexusDx: What Is GLP-1, GLP-1 What Is, GLP-1 Receptor Agonist, GLP-1 Drugs.

Editorial note: this comparison is educational. PlexusDx sells semaglutide and tirzepatide through its own Weight Management Protocols and is unaffiliated with the reviewed brands. The Precision Peptide Genetic Test reports genetic influence on peptide pathways and does not predict medication response. Consult a qualified provider before starting a protocol.

Frequently Asked Questions

Is Ro better for weight loss than Ivim Health?

Neither is universally better. Ro offers a broad catalog convenient if you want multiple services in one place, while Ivim Health focuses on metabolic care and compounded options. The right choice depends on whether breadth or a narrower metabolic focus matters more to you.

Do Ro and Ivim Health offer compounded medication?

Both can prescribe branded FDA-approved GLP-1 products or compounded semaglutide or tirzepatide from licensed pharmacies, with Ivim Health emphasizing a compounded pathway. Which formulation you receive depends on eligibility and the current catalog, so verify on each brand own site.

Does a focused program mean better metabolic support?

A focused program may devote more attention to the metabolic use case, but a broad platform can still provide solid support. Evaluate the specifics, provider type, titration guidance, and follow-up, rather than assuming scope alone determines the quality of care.

How does genetic testing fit either program?

Genetic testing sits upstream of both. The Precision Peptide Genetic Test maps variants such as GLP1R and FTO that describe your baseline metabolic biology, giving context that applies whether you choose a broad-catalog telehealth service or a focused metabolic program.

This article belongs to the PlexusDx Education Hub. Browse all Peptides & GLP-1 education